Tumor therapy by targeting extracellular hydroxyapatite using novel drugs: A paradigm shift

Mohammed N. Tantawy,J. Oliver McIntyre,Fiona Yull,M. Wade Calcutt,Dmitry S. Koktysh,Andrew J. Wilson,Zhongliang Zu,Jeff Nyman,Julie Rhoades,Todd E. Peterson,Daniel Colvin,Lisa J. McCawley,Jerri. M. Rook,Barbara Fingleton,Marta Ann Crispens,Ronald D. Alvarez,John C. Gore
DOI: https://doi.org/10.1002/cam4.6812
IF: 4.711
2024-01-20
Cancer Medicine
Abstract:We have developed a cation ion nanoparticulate sulfonated polystyrene solution (NSPS) to target and chelate tumor microenvironment hydroxyapatite (TME‐HAP) releasing phosphate and hydroxyl ions in the TME and subsequently inducing acute localized alkalosis. Chelation of TME‐HAP with NSPS resulted in the inhibition of tumor cell metabolism and proliferation leading to tumor cell apoptosis in mouse models. There are no other known injectable compounds that can break up TME‐HAP in vivo making NSPS a one‐of‐a‐kind and first in a class of novel cancer therapeutics. Background It has been shown that tumor microenvironment (TME) hydroxyapatite (HAP) is typically associated with many malignancies and plays a role in tumor progression and growth. Additionally, acidosis in the TME has been reported to play a key role in selecting for a more aggressive tumor phenotype, drug resistance and desensitization to immunotherapy for many types of cancers. TME‐HAP is an attractive target for tumor detection and treatment development since HAP is generally absent from normal soft tissue. We provide strong evidence that dissolution of hydroxyapatite (HAP) within the tumor microenvironment (TME‐HAP) using a novel therapeutic can be used to kill cancer cells both in vitro and in vivo with minimal adverse effects. Methods We developed an injectable cation exchange nano particulate sulfonated polystyrene solution (NSPS) that we engineered to dissolve TME‐HAP, inducing localized acute alkalosis and inhibition of tumor growth and glucose metabolism. This was evaluated in cell culture using 4T1, MDA‐MB‐231 triple negative breast cancer cells, MCF10 normal breast cells, and H292 lung cancer cells, and in vivo using orthotopic mouse models of cancer that contained detectable microenvironment HAP including breast (MMTV‐Neu, 4T1, and MDA‐MB‐231), prostate (PC3) and colon (HCA7) cancer using 18F‐NaF for HAP and 18F‐FDG for glucose metabolism with PET imaging. On the other hand, H292 lung tumor cells that lacked detectable microenvironment HAP and MCF10a normal breast cells that do not produce HAP served as negative controls. Tumor microenvironment pH levels following injection of NSPS were evaluated via Chemical Exchange Saturation (CEST) MRI and via ex vivo methods. Results Within 24 h of adding the small concentration of 1X of NSPS (~7 μM), we observed significant tumor cell death (~ 10%, p
oncology
What problem does this paper attempt to address?